MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

AMBLor® Melanoma Prognostic Biomarker Achieves UKCA Certification

NextEdge Admin

04 Sep 2024

2 min 23 sec

AMBLor® is a pioneering histopathological biomarker test designed to identify early-stage melanomas at low risk of progression following staging diagnosis. As the first in vitro diagnostic (IVD) test of its kind, AMBLor can accurately stratify non-ulcerated AJCC stage I-II melanomas unlikely to metastasize, potentially sparing patients from unnecessary diagnostic procedures and extended follow-up schedules. With its recent UKCA certification, AMBLor is now available to healthcare professionals in Great Britain.

The nationwide adoption of AMBLor could alleviate pressure on NHS waiting lists, which have seen a 25% increase in patients awaiting skin cancer treatment. By identifying low-risk melanomas, AMBLor could free up appointments for other patients, addressing the current backlog.

Using the patient’s original skin biopsy, AMBLor detects two prognostic proteins, AMBRA1 and loricrin. The absence of these biomarkers signals a higher risk of metastasis, while their presence indicates a low risk of progression. Recent validation data showed AMBLor’s negative predictive value at 96.5%, underscoring its accuracy in identifying low-risk tumours.

Currently, around 20% of early-stage melanomas progress to metastatic disease, necessitating extensive follow-up and invasive procedures like sentinel lymph node biopsy, which carries a significant complication rate. AMBLor’s introduction offers the potential for a more personalized approach to disease management, reducing patient anxiety and the burden on healthcare resources.

Dr. Marie Labus, CEO of AMLo Biosciences, and Mr. Aidan Rose, Consultant Plastic Surgeon, both emphasized the potential of AMBLor to improve clinical decision-making and ease the strain on healthcare services.